Oxford Nanopore Technologies
plc
London
Calling Technology Update
Announcements highlighted breakthrough technology performance
and updates to Oxford Nanopore's IVD pipeline at annual customer
conference
23 May 2024
Oxford Nanopore Technologies plc
(LSE: ONT) ("Oxford Nanopore" or the "Company"), the company
delivering a new generation of nanopore-based molecular sensing
technology, presented breakthrough
performance data and new platform updates at the Company's annual
London Calling customer conference, held between 21 and 24 May
2024. During the sold-out event, with more
than 5,500 registered on-line and in-person participants, the
Company also provided updates to its clinical product pipeline,
unveiling a new roadmap for its first IVD product ahead of its
first clinical and biopharma day on Friday.
Technology updates
included:
· Delivering increasingly rich, high performance multiomic
data: The update focused on improved
performance on accuracy, delivering
complete genomes with nanopore-only
Telomere-to-Telomere (T2T) sequencing, and full-length chromosomes
in a single read, illustrated by successful T2T reads of four yeast
chromosomes as proof of concept.
· Improving direct RNA sequencing to support breakthrough
science and biopharma workflows: higher
accuracy and output for direct RNA sequencing alongside the example
of integrated, real-time quality control (QC) test for mRNA
vaccines.
· Pipeline updates, enabling ultra-high output and accessible,
distributed sequencing for anyone, anywhere: with the MinION Mk1D entering early access, continued progression with TraxION, enabling
portable library prep in the field, the Voltage chip for ultra-rapid
whole genome sequencing (WGS) and
the new prototype of Oxford Nanopore's smallest
sequencer to date - the SmidgION - which was on display at
the event.
A written summary and a video replay
of the technology talk can be accessed on the Oxford Nanopore
website
here.
This morning, the Company will
present a product review including an update on progress to its
regulated product pipeline. In addition to locked-down Q line
devices, the GridION is expected to meet ISO 13485 standards in
2025 and the Company will seek CE-IVD certification in the EU after
that. The device will be available for specified partners
only. The GridION Q-Line product range is on track to launch
shortly in Q3-2024, as previously announced.
Alongside the technology updates the
Company will also provide more details at its first clinical and
biopharma day on Friday.
[ENDS]
For further information, please
contact:
Oxford Nanopore Technologies plc
Investors: ir@nanoporetech.com
Media: media@nanoporetech.com
Teneo (communications adviser to the
Company)
Tom Murray, Olivia Peters
+44 (0) 20 7353 4200
OxfordNanoporeTechnologies@teneo.com
About Oxford Nanopore Technologies plc:
Oxford Nanopore Technologies' goal is
to bring the widest benefits to society through enabling the
analysis of anything, by anyone, anywhere. The company has
developed a new generation of nanopore-based sensing technology for
real-time, high-performance, accessible and scalable analysis of
DNA and RNA. The technology is used in more than 120 countries to
understand the biology of humans and diseases such as cancer,
plants, animals, bacteria, viruses and whole environments. Oxford
Nanopore Technologies products are intended for molecular biology
applications and are not intended for diagnostic
purposes. www.nanoporetech.com
Forward-looking statements
This announcement contains certain
forward-looking statements. For example, statements regarding
expected revenue growth and profit margins are forward-looking
statements. Phrases such as "aim", "plan", "expect", "intend",
"anticipate", "believe", "estimate", "target", and similar
expressions of a future or forward-looking nature should also be
considered forward-looking statements. Forward-looking statements
address our expected future business and financial performance and
financial condition, and by definition address matters that are, to
different degrees, uncertain. Our results could be affected by
macroeconomic conditions, the COVID-19 pandemic, delays in our
receipt of components or our delivery of products to our customers,
suspensions of large projects and/or acceleration of large products
or accelerated adoption of pathogen surveillance. These or other
uncertainties may cause our actual future results to be materially
different than those expressed in our forward-looking
statements.